JADE BIOSCIENCES INC (JBIO) Fundamental Analysis & Valuation

NASDAQ:JBIO • US0080642061

Current stock price

14 USD
-0.08 (-0.57%)
At close:
14 USD
0 (0%)
After Hours:

This JBIO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. JBIO Profitability Analysis

1.1 Basic Checks

  • In the past year JBIO has reported negative net income.
  • JBIO had a negative operating cash flow in the past year.
  • In the past 5 years JBIO always reported negative net income.
  • In the past 5 years JBIO always reported negative operating cash flow.
JBIO Yearly Net Income VS EBIT VS OCF VS FCFJBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

1.2 Ratios

  • JBIO has a Return On Assets of -20.84%. This is in the better half of the industry: JBIO outperforms 75.44% of its industry peers.
  • JBIO has a Return On Equity of -21.92%. This is amongst the best in the industry. JBIO outperforms 81.43% of its industry peers.
Industry RankSector Rank
ROA -20.84%
ROE -21.92%
ROIC N/A
ROA(3y)-58.19%
ROA(5y)-45.15%
ROE(3y)-63.4%
ROE(5y)-48.84%
ROIC(3y)N/A
ROIC(5y)N/A
JBIO Yearly ROA, ROE, ROICJBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -200 -400 -600 -800

1.3 Margins

  • JBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JBIO Yearly Profit, Operating, Gross MarginsJBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. JBIO Health Analysis

2.1 Basic Checks

  • JBIO has more shares outstanding than it did 1 year ago.
  • JBIO has more shares outstanding than it did 5 years ago.
  • JBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
JBIO Yearly Shares OutstandingJBIO Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
JBIO Yearly Total Debt VS Total AssetsJBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 23.69 indicates that JBIO is not in any danger for bankruptcy at the moment.
  • JBIO has a Altman-Z score of 23.69. This is amongst the best in the industry. JBIO outperforms 90.52% of its industry peers.
  • JBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.69
ROIC/WACCN/A
WACCN/A
JBIO Yearly LT Debt VS Equity VS FCFJBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M

2.3 Liquidity

  • JBIO has a Current Ratio of 21.09. This indicates that JBIO is financially healthy and has no problem in meeting its short term obligations.
  • JBIO has a better Current ratio (21.09) than 96.33% of its industry peers.
  • A Quick Ratio of 21.09 indicates that JBIO has no problem at all paying its short term obligations.
  • The Quick ratio of JBIO (21.09) is better than 96.33% of its industry peers.
Industry RankSector Rank
Current Ratio 21.09
Quick Ratio 21.09
JBIO Yearly Current Assets VS Current LiabilitesJBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. JBIO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 94.05% over the past year.
EPS 1Y (TTM)94.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, JBIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.71% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y61.57%
EPS Next 2Y25.91%
EPS Next 3Y13.63%
EPS Next 5Y8.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
JBIO Yearly EPS VS EstimatesJBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 -20 -40 -60 -80 -100

More info and screens

Find the best growth stocksShow best growing peers

0

4. JBIO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for JBIO. In the last year negative earnings were reported.
  • Also next year JBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JBIO Price Earnings VS Forward Price EarningsJBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JBIO Per share dataJBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as JBIO's earnings are expected to grow with 13.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.91%
EPS Next 3Y13.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. JBIO Dividend Analysis

5.1 Amount

  • JBIO has a Yearly Dividend Yield of 603.45%, which is a nice return.
  • JBIO's Dividend Yield is rather good when compared to the industry average which is at 1.27. JBIO pays more dividend than 100.00% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.91, JBIO pays a better dividend.
Industry RankSector Rank
Dividend Yield 603.45%

5.2 History

  • JBIO is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
JBIO Yearly Dividends per shareJBIO Yearly Dividends per shareYearly Dividends per share 2025 20 40 60 80

5.3 Sustainability

DPN/A
EPS Next 2Y25.91%
EPS Next 3Y13.63%
JBIO Yearly Income VS Free CF VS DividendJBIO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

More info and screens

Find the best dividend stocksShow peers with best dividend

JBIO Fundamentals: All Metrics, Ratios and Statistics

JADE BIOSCIENCES INC

NASDAQ:JBIO (3/20/2026, 8:02:45 PM)

After market: 14 0 (0%)

14

-0.08 (-0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-06
Earnings (Next)04-20
Inst Owners100.86%
Inst Owner Change43.86%
Ins Owners1.36%
Ins Owner Change29.77%
Market Cap690.34M
Revenue(TTM)N/A
Net Income(TTM)-72.90M
Analysts88.57
Price Target22.44 (60.29%)
Short Float %3.25%
Short Ratio5.5
Dividend
Industry RankSector Rank
Dividend Yield 603.45%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)4.12%
Min EPS beat(2)-21.95%
Max EPS beat(2)30.18%
EPS beat(4)2
Avg EPS beat(4)-5.84%
Min EPS beat(4)-94.83%
Max EPS beat(4)63.24%
EPS beat(8)4
Avg EPS beat(8)-0.13%
EPS beat(12)4
Avg EPS beat(12)-1.73%
EPS beat(16)5
Avg EPS beat(16)-5.77%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)6.45%
EPS NQ rev (1m)-1.31%
EPS NQ rev (3m)1.44%
EPS NY rev (1m)0%
EPS NY rev (3m)2.52%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.08
P/tB 2.08
EV/EBITDA N/A
EPS(TTM)-5.08
EYN/A
EPS(NY)-1.95
Fwd EYN/A
FCF(TTM)-1.92
FCFYN/A
OCF(TTM)-1.92
OCFYN/A
SpS0
BVpS6.74
TBVpS6.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -20.84%
ROE -21.92%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.19%
ROA(5y)-45.15%
ROE(3y)-63.4%
ROE(5y)-48.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 753.85%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.09
Quick Ratio 21.09
Altman-Z 23.69
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)94.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.11%
EPS Next Y61.57%
EPS Next 2Y25.91%
EPS Next 3Y13.63%
EPS Next 5Y8.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-25.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-33.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-33%
OCF growth 3YN/A
OCF growth 5YN/A

JADE BIOSCIENCES INC / JBIO Fundamental Analysis FAQ

What is the fundamental rating for JBIO stock?

ChartMill assigns a fundamental rating of 3 / 10 to JBIO.


What is the valuation status for JBIO stock?

ChartMill assigns a valuation rating of 0 / 10 to JADE BIOSCIENCES INC (JBIO). This can be considered as Overvalued.


Can you provide the profitability details for JADE BIOSCIENCES INC?

JADE BIOSCIENCES INC (JBIO) has a profitability rating of 1 / 10.


Can you provide the financial health for JBIO stock?

The financial health rating of JADE BIOSCIENCES INC (JBIO) is 8 / 10.